Hormone therapy and TRT clinic profitability: the recurring-revenue math

A hormone clinic is a maintenance business, not a procedure business

Most owners size up a hormone-optimization clinic the way they would size up a med spa: count the consults, multiply by a price, and call it revenue. That misses what actually makes a TRT or BHRT practice work. A hormone clinic is not really selling a treatment. It is selling a relationship that renews month after month, where the heavy work happens once, at the start, and then settles into something light and repeatable. The economics live in that shape. Get the intake right, stabilize the patient, and the same person keeps paying for years while consuming very little of your most expensive resource, which is provider time.

That structure is what separates hormone therapy from the other recurring cash-pay program everyone is chasing right now. A GLP-1 weight-loss program is mostly pass-through drug cost: the medication is expensive, the margin rides on a markup, and the patient needs a touch every month indefinitely. Hormones flip both of those. Many of the drugs cost very little per dose, and a stabilized patient needs only periodic labs and a light check-in. The result is a margin profile that is healthier at the drug line and a time profile that gets more profitable the longer a patient stays.

Where the money actually comes from

A hormone clinic earns across four distinct lines, and they behave very differently. Knowing which line carries the practice is the whole game, because the busiest line and the most profitable line are rarely the same one, the same trap behind a busy service that loses money.

• The intake. Initial consult plus a baseline lab panel, and often a starting protocol. This is your most provider-heavy moment and usually a one-time or annual charge. It is where you earn the right to the recurring revenue, not where the recurring profit lives.
• The ongoing program. A monthly or quarterly membership that covers the prescription, periodic monitoring labs, and light follow-up. This is the engine. It renews, it consumes little time once a patient is stable, and most hormone medications cost little per dose, so the margin is genuinely healthy.
• Periodic labs. Follow-up panels every few months to keep dosing safe and dialed in. Depending on your arrangement, these can be a modest margin line or close to a pass-through, but they are clinically necessary and they create a natural recurring touchpoint.
• Procedures. Pellet insertions are the main one: a short in-office procedure billed as a discrete fee, performed once a quarter or so for the patients on that route. Higher per-visit revenue, real provider time, and a consumable cost per insertion.

The mistake is treating the intake as the product. The intake is the cost of acquiring a recurring patient. The product is the years of low-time, low-drug-cost maintenance that follow, and that is where you should be measuring whether the practice is actually profitable.

Why the drug cost is the good news

This is the line that makes people who come from a GLP-1 background do a double take. A vial of injectable testosterone, depending on concentration and how you source it, can cover a patient for many weeks at a marginal cost that is small relative to what the program charges. Compounded BHRT and many oral or topical preparations sit in a similar place. None of this is a medical claim, it is purely a cost observation: the drug is usually not the expensive part of a hormone program.

Contrast the two recurring models directly. In a GLP-1 program, the medication can be the largest single cost in the whole program, so your margin is a markup on a pass-through and it moves with drug pricing you do not control. In a hormone program, the drug is a minor line, so the margin is mostly a function of your provider time and your overhead, both of which you do control. That is a structurally better position to be in. It also means the number that decides your profit is not the drug, it is how much each provider-hour earns.

In a GLP-1 program the drug is the cost and your job is to defend a markup. In a hormone program the drug is a rounding error and your job is to defend your provider time. Two recurring-revenue businesses, two completely different things to protect.

One caution worth stating plainly: sourcing, compounding, and what you are permitted to dispense or markup vary widely by state, by your medical-director arrangement, and by whether you work with a compounding pharmacy or dispense in-house. The low marginal cost is real, but the legal and operational structure around it is not uniform, so treat the drug-cost figures here as illustrative of the shape, not a quote.

The intake-versus-maintenance time profile

Here is the second thing that makes hormone clinics quietly profitable: provider time is heavily front-loaded. A new patient might consume an hour or more across the initial consult, lab review, and protocol design. A stable patient, six months later, might need fifteen minutes a quarter. The cost to serve a patient drops dramatically after the first few months, but the revenue keeps renewing at close to the same rate.

That is the opposite of a procedure-driven practice, where every dollar of revenue requires a fresh block of provider time. It means your profit per provider-hour on a hormone patient is low in month one and climbs steeply as they stabilize. A panel of stabilized maintenance patients is one of the highest profit-per-hour assets a cash-pay clinic can own, because each one renews while asking for almost none of the scarce resource.

What this means for how you staff and book

• Protect intake capacity, but do not let it own the schedule. Intakes are how you grow the recurring base, so you need slots for them. But an hour of intake earns far less per minute than an hour of stabilized maintenance touches stacked back to back.
• Delegate the light maintenance touches. Routine follow-ups, lab reviews, and refills can often run through an advanced-practice provider or staff under a physician's oversight, depending on your state and supervision rules. The intake stays with your most expensive clinician; the maintenance does not have to.
• Measure the panel, not the appointment. The right unit of profit here is the annual contribution of a maintenance patient against the provider-hours they consume in a year, not the price of any single visit.

Pricing the program and the labs

Because the value is recurring, the program fee is the most important number you set, and it should be built the same disciplined way you would build any price: from the cost to serve, the provider time consumed, and a target profit per provider-hour, not from what the clinic down the road charges. The method behind pricing a service from cost and time applies cleanly, with one adjustment: you are pricing a year of light touches plus cheap drug, not a single appointment.

1. Total the annual cost to serve a stabilized patient: the drug for the year, the monitoring labs you include, and the consumables. For most hormone protocols this total is modest.
2. Add the provider-hours a stable patient consumes in a year, realistically. For a maintenance patient this is often only an hour or two across the whole year once intake is behind them.
3. Layer in the overhead share for those provider-hours, exactly as you would for any service. This is the floor the program fee must clear.
4. Add your target profit per provider-hour on the time consumed. Divide the annual total by twelve and you have the lowest monthly fee that hits your target.
5. Price the intake separately as its own line, so the heavy first-month time is paid for up front and is not silently subsidized by the recurring fee.

Lab economics

Labs are clinically required and they can be either a quiet margin line or close to a pass-through, depending entirely on your arrangement. If you draw in-house and contract a reference lab at a wholesale rate, there is often room between your cost and a fair patient price. If you send patients out to a third party, the lab may carry little or no margin and simply serve as a necessary, recurring reason for the patient to stay engaged. Either way, decide deliberately whether labs are a profit line or a retention tool, and price the program accordingly. What you must not do is bundle a generous lab cadence into a flat fee without checking that the fee still clears your floor when every included panel is actually run.

Pellet-procedure economics

Pellets behave differently from the rest of the program because they are a discrete procedure with real provider time and a real consumable cost per insertion. A pellet insertion is typically billed as a per-procedure fee, the pellets themselves cost something per insertion, and the procedure occupies a focused block of provider time, often shorter than people expect but not trivial. Done a few times a year per patient, it is a solid recurring revenue line on top of the base program.

Treat it on its own profit-per-hour terms. The thing that erodes pellet margin is not the consumable, which is fairly contained, it is letting your most expensive clinician spend a long block on a procedure that an appropriately trained, properly supervised provider could perform. As with every line here, the supervision and scope rules vary by state and setup, so the delegation question has a legal answer before it has a financial one. But where delegation is permitted, it is one of the cleaner ways to lift the profit per provider-hour of the procedure side.

Every line in a hormone clinic eventually points back to the same question: what is an hour of provider time earning on this, and is the most expensive clinician in the building spending it on the work that only they can do?

A worked example

Take one stabilized maintenance patient on a monthly program (illustrative figures, in a conservative range, not a specific clinic). The intake was billed and earned separately the year before; this is the recurring year that follows. Use these inputs:

• Program fee: $150 a month, so $1,800 collected over the year.
• Annual drug cost: roughly $180 for the year of injectable testosterone.
• Included monitoring labs: about $200 in lab cost across the year.
• Provider time consumed: roughly 1.5 hours total across the whole year of light follow-ups and refills.
• Overhead share: $80 per provider-hour, so about $120 for the year.

Now run the math. The patient pays $1,800. Against that you spend $180 in drug, $200 in labs, and $120 in overhead, which totals $500. Annual contribution is $1,800 minus $500, or $1,300, on about 1.5 provider-hours. That works out to roughly $867 of profit per provider-hour ($1,300 divided by 1.5), an exceptionally strong figure that exists only because the drug is cheap and the maintenance time is light.

Maintenance profit per provider-hour = (annual fee minus drug minus labs minus overhead share) divided by provider-hours consumed. Here: ($1,800 minus $180 minus $200 minus $120) divided by 1.5 hours = $1,300 divided by 1.5 = about $867 per hour.

Now look at the same patient in their first year, when intake time is included. Suppose the intake added 1.5 hours of provider time on its own, bringing the year to 3 hours, and the baseline panel added $150 of lab cost. Drug stays $180, labs become $350, and overhead at $80 per hour over 3 hours becomes $240, for $770 of total cost. If the intake was bundled into the program rather than billed separately, contribution would fall to $1,800 minus $770, or $1,030 over 3 hours, which is roughly $343 per provider-hour ($1,030 divided by 3). Same patient, same fee, well under half the profit per hour, purely because the heavy first-year time was not paid for up front. That gap is exactly why you price the intake as its own line and why the recurring math only looks as good as it does after a patient is stable.

It is also why the headline figure can mislead. A clinic full of brand-new intakes and a clinic full of stabilized maintenance patients can show the same monthly revenue and earn completely different profit, the same way revenue can climb while profit falls when the mix shifts underneath you.

See it on a full sample practice

A hormone clinic is one of the better recurring-revenue models in cash-pay medicine, but only if you measure the right unit. Revenue per patient tells you almost nothing here, because the same fee can represent a time-and-drug-heavy first year or a nearly free year of maintenance. The number that tells the truth is the annual contribution of a patient against the provider-hours they actually consume, ranked beside every other line in the practice. The Inside Look walks a complete sample practice through exactly that view: every service and program ranked by profit per provider-hour, with a forecaster that shows how repricing a program or shifting maintenance to a delegated provider ripples to the bottom line, no new patients required.

If you are building or repricing a program, start with the method behind which of your cash-pay services actually make money, then pressure-test the fee against profit per provider-hour so the recurring revenue you are working so hard to build is recurring profit, not a busier version of the same take-home. Price the maintenance like the high-margin, low-time asset it really is, and the years of renewals compound in your favor.